Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date
Rhea-AI Filing Summary
Silexion Therapeutics Corp filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment is narrowly focused on correcting typographical errors in Item 9A so that the date of management’s evaluation of internal control over financial reporting is properly stated as December 31, 2025 rather than December 31, 2024.
Management, including the Chief Executive Officer and Chief Financial Officer, evaluated disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework and concluded both were effective. As a non-accelerated, emerging growth company, Silexion is not required to obtain an auditor attestation on internal control.
The company states there were no changes in internal control over financial reporting during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, these controls. Other disclosures from the original Form 10-K remain unchanged, aside from updated exhibits and certifications. As of June 30, 2025, non-affiliate ordinary shares had an aggregate market value of $6,619,600, and 3,330,785 ordinary shares were outstanding as of March 10, 2026.
Positive
- None.
Negative
- None.
Key Figures
Non-affiliate shares: 8,172,750 ordinary shares
Market value non-affiliate float: $6,619,600
Share price reference: $0.81 per share
+3 more
6 metrics
Non-affiliate shares
8,172,750 ordinary shares
Held by non-affiliates as of June 30, 2025
Market value non-affiliate float
$6,619,600
Based on $0.81 Nasdaq closing price on June 30, 2025
Share price reference
$0.81 per share
Nasdaq closing price on June 30, 2025 before 1-for-15 reverse split
Shares outstanding
3,330,785 ordinary shares
Issued and outstanding as of March 10, 2026
Warrant exercise price
$1,552.50 per share
Exercise price for listed warrants trading as SLXNW
Authorized share capital
59,000,000 ordinary shares
Authorized under $796,500 share capital at $0.0135 par value
Key Terms
disclosure controls and procedures, internal control over financial reporting, emerging growth company, reverse share split, +2 more
6 terms
disclosure controls and procedures regulatory
"We maintain “disclosure controls and procedures” as such term is defined in Rules 13a-15(e)..."
Policies, routines and internal checks a public company uses to identify, collect and verify information that must appear in its financial reports and public filings, and to make sure that material news is disclosed accurately and on time. Investors care because effective controls increase confidence that the company’s reported numbers and disclosures are reliable and reduce the risk of surprises, much like a building’s inspection and alarm system helps occupants trust the structure’s safety.
internal control over financial reporting regulatory
"Our management is responsible for establishing and maintaining adequate internal control over financial reporting..."
Internal control over financial reporting is a company’s system of procedures and checks designed to make sure its financial statements are accurate and complete, like a set of guardrails and verification steps that catch mistakes or fraud before numbers are published. Investors care because strong controls make reported results more trustworthy, lower the risk of surprise restatements or regulatory problems, and give greater confidence when valuing the company or comparing it to peers.
emerging growth company regulatory
"We are an emerging growth company, and are furthermore neither an accelerated filer nor a large accelerated filer..."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
At‑The‑Market Offering Agreement financial
"At‑The‑Market Offering Agreement, dated September 26, 2025, by and between Silexion Therapeutics Corp and H.C. Wainwright & Co., LLC..."
Inline XBRL technical
"101.INS*Inline XBRL Instance Document. 101.SCH*Inline XBRL Taxonomy Extension Schema Document..."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is Silexion Therapeutics Corp (SLXN) changing in this 10-K/A?
Silexion is correcting the date for management’s internal control evaluation to December 31, 2025. The amendment restates Item 9A, updates certain exhibits and certifications, and leaves all other original Form 10-K disclosures unchanged.
How did Silexion (SLXN) assess its internal control over financial reporting?
Management evaluated internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework. They concluded controls were effective in providing reasonable assurance over reliable financial reporting and U.S. GAAP-compliant financial statements.
Did Silexion report any material changes in internal control in late 2025?
No. Silexion states there were no changes during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, internal control over financial reporting. This supports continuity of the control environment at year-end.
Is Silexion (SLXN) required to obtain an auditor attestation on internal control?
No. Silexion is an emerging growth company and a non-accelerated filer under Exchange Act rules. Because of this status, it is not required to include a registered public accounting firm’s attestation report on management’s assessment of internal control.
What securities of Silexion (SLXN) are listed on Nasdaq?
Silexion lists ordinary shares with a par value of $0.0135 per share under symbol SLXN, and warrants exercisable for ordinary shares at an exercise price of $1,552.50 per share under symbol SLXNW. Both classes trade on The Nasdaq Stock Market LLC.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
Amendment No. 1
EXCHANGE ACT OF 1934
For the fiscal year ended December 31 , 2025
EXCHANGE ACT OF 1934
For the transition period from _______________ to _______________
Commission File Number 001-39157
(Exact name of registrant as specified in its charter)
|
|
|
001-42253
|
|
N/A
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: +972 -3 756-4999
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on
which registered |
|
|
|
|
|
|
|
|
|
|
|
|
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
|
☒
|
Smaller reporting company
|
|
|
Emerging growth company
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
As of June 30, 2025 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s ordinary shares held by non-affiliates (based on 8,172,750 ordinary shares held by no n-affiliates as of that date and an $0.81 closing price of the ordinary shares on Nasdaq on that date (neither of which reflects the subsequent 1-for-15 reverse share split effected by the registrant on July 29, 2025) was $6,619,600.
As of March 10, 2026, 3,330,785 ordinary shares, par value $0.0135 per share, were issued and outstanding.
Documents Incorporated by Reference: None.
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (this “Amendment”) to the Annual Report on Form 10-K of Silexion Therapeutics Corp (the “Company”, “we”, “us” or “our”) for the fiscal year ended December 31, 2025, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2026 (the “Original 10-K”), is being filed solely to amend and restate Part II “Item 9A. Controls and Procedures” to correct typographical errors whereby the date as of which the Company’s management evaluated the effectiveness of our internal control over financial reporting is stated as December 31, 2024 whereas that evaluation was actually carried out as of December 31, 2025. Those typographical errors are corrected in this Amendment.
This Amendment contains only the cover page, this explanatory note, the complete text of Item 9A, the exhibit list, a signature page and the certifications of the Company’s principal executive and financial and accounting officers under the Sarbanes Oxley Act of 2002, as amended.
Other than as expressly set forth herein (including updated versions of Exhibits 3.5 and 10.5.2 listed in the exhibit index, which reflect updated versions of matters included in the Original 10-K that have been approved by our shareholders since the filing of the Original 10-K), this Amendment does not, and does not purport to, amend, update or restate the information in the Original 10-K or reflect any events that have occurred after the Original 10-K was filed. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original 10-K was filed. This Amendment should be read together with the Original 10-K and the Company’s other filings with the SEC.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures” as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
As of the end of the period covered by this Annual Report, we carried out an evaluation, under the supervision and with the participation of our senior management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.
Management’s Report on Internal Control over Financial Reporting; Attestation Report of the Registered Public Accounting Firm.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
Under the supervision and with the participation of our management, including our principal executive officers and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2025.
We are an emerging growth company, and are furthermore neither an accelerated filer nor a large accelerated filer, in each case as defined in Rule 12b-2 under the Exchange Act. Therefore, we are not required under Section 202 of the Sarbanes-Oxley Act (and the SEC rules and regulations thereunder) to provide an attestation report on management’s assessment of our internal control over financial reporting from a registered public accounting firm in this Annual Report.
Changes in Internal Control over Financial Reporting
Based on the evaluation conducted by our senior management, including our Chief Executive Officer and Chief Financial Officer, we have concluded that there has been no change that occurred during the three-month period ended December 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART IV
Item 15. Exhibits and Financial Statement Schedules
|
(a)
|
The following documents were filed as part of the Original 10-K:
|
|
(1)
|
Our financial statements as of, and for the year ended December 31, 2025, which were included in the “F-“ pages of the Original 10-K.
|
|
(3)
|
The exhibits are listed in the following Exhibit Index:
|
|
Exhibit No.
|
|
Description
|
|
3.1
|
|
Amended and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
|
|
3.2
|
|
Ordinary Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)
|
|
3.3
|
|
Ordinary Resolution Effecting 1‑for‑15 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on July 29, 2025)
|
|
3.4
|
|
Ordinary Resolution Approving Increase in Authorized Share Capital to $121,500 (9,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on August 19, 2025)
|
|
3.5
|
Ordinary Resolution Approving Increase in Authorized Share Capital to $796,500 (59,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on May 5, 2026)
|
|
|
4.1*
|
Description of Securities of Silexion Therapeutics Corp registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended
|
|
|
4.2
|
|
Warrant Agreement, dated February 19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Moringa Acquisition Corp’s Current Report on Form 8-K, filed with the SEC on February 22, 2021)
|
|
4.3
|
|
Assignment, Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
|
|
4.4
|
|
Warrant Adjustment Notice, dated November 29, 2024, in respect of 1-for-9 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)
|
|
4.5
|
|
Warrant Adjustment Notice, dated July 29, 2025, in respect of 1‑for‑15 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on July 29, 2025)
|
|
10.1
|
|
Amended and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.’s pre-Business Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
|
|
10.2
|
|
Amended and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
|
|
10.3
|
|
Form of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
|
|
10.4.1#
|
|
Employment Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1 to Amendment No. 3 to the Company’s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024).
|
|
10.4.2#
|
|
Amendment No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.2 to Amendment No. 3 to the Company’s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)
|
|
10.5.1#
|
|
Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
|
|
10.5.2#
|
Amendment to Section 5(b)(i) of the Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Annex C to Silexion Therapeutics Corp’s Proxy Statement on Schedule 14A, filed with the SEC on April 9, 2026)
|
|
|
10.6#
|
|
Silexion Therapeutics Ltd. 2013 Share Option Plan (incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp’s Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)
|
|
10.7
|
|
Form of Ordinary Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)
|
|
10.8
|
|
Form of Placement Agent Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)
|
|
10.9
|
|
Form of Ordinary Share Purchase Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)
|
|
10.10
|
|
Form of Placement Agent Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)
|
|
10.11
|
|
Form of Ordinary Share Purchase Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 1, 2025)
|
|
10.12
|
|
Form of Placement Agent Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 1, 2025)
|
|
10.13
|
|
Form of Series A Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)
|
|
10.14
|
|
Form of Series B Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)
|
|
10.15
|
|
Form of Placement Agent Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.4 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)
|
|
10.16
|
|
At‑The‑Market Offering Agreement, dated September 26, 2025, by and between Silexion Therapeutics Corp and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 26, 2025)
|
|
19.1
|
|
Insider Trading Policy of Silexion Therapeutics Corp (incorporated by reference to Exhibit 19.1 to Silexion Therapeutics Corp’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)
|
|
21.1*
|
List of Subsidiaries
|
|
|
23.1*
|
Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm of Silexion Therapeutics Corp
|
|
|
31.1**
|
Certification of Silexion Therapeutics Corp’s Chief Executive Officer (Principal Executive Officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
31.2**
|
Certification of Silexion Therapeutics Corp’s Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
32.1***
|
Certification of Silexion Therapeutics Corp’s Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
97.1
|
Silexion Therapeutics Corp Policy for Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to Silexion Therapeutics Corp’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)
|
101.INS*Inline XBRL Instance Document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
|
* Filed with the Original 10-K.
|
** Filed with this Amendment.
*** Furnished with this Amendment.
# Indicates management contract or compensatory plan, contract or arrangement.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Silexion Therapeutics Corp
|
|
|
|
|
|
By:
|
/s/ Ilan Hadar
|
|
Name:
|
Ilan Hadar
|
|
Title:
|
Chairman of the Board and Chief Executive Officer
|
|
Date:
|
May 19, 2026
|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
|
Name
|
|
Position
|
|
Date
|
|
|
|
|
|
|
|
/s/ Ilan Hadar
|
|
Chairman of the Board and Chief Executive Officer
|
|
May 19, 2026
|
|
Ilan Hadar
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Mirit Horenshtein Hadar
|
|
Chief Financial Officer
|
|
May 19, 2026
|
|
Mirit Horenshtein Hadar
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Ruth Alon
|
|
Director
|
|
May 19, 2026
|
| Ruth Alon |
| /s/ Dror Abramov |
Director
|
|
May 19, 2026
|
|
|
Dror Abramov
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Avner Lushi
|
|
Director
|
|
May 19, 2026
|
|
Avner Lushi
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Shlomo Noy
|
|
Director
|
|
May 19, 2026
|
|
Shlomo Noy
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Amnon Peled
|
|
Director
|
|
May 19, 2026
|
| Amnon Peled |